JP2010507577A - トリアゾロピリダジンタンパク質キナーゼモジュレーター - Google Patents

トリアゾロピリダジンタンパク質キナーゼモジュレーター Download PDF

Info

Publication number
JP2010507577A
JP2010507577A JP2009533536A JP2009533536A JP2010507577A JP 2010507577 A JP2010507577 A JP 2010507577A JP 2009533536 A JP2009533536 A JP 2009533536A JP 2009533536 A JP2009533536 A JP 2009533536A JP 2010507577 A JP2010507577 A JP 2010507577A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
pyridinyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009533536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507577A5 (OSRAM
Inventor
クリストファー・ロナルド・スミス
ピエール−イヴ・ブーノー
エリザベス・アン・ジェファーソン
パトリック・エス・リー
エドゥアルド・トレス
Original Assignee
エスジーエックス ファーマシューティカルズ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスジーエックス ファーマシューティカルズ、インコーポレイテッド filed Critical エスジーエックス ファーマシューティカルズ、インコーポレイテッド
Publication of JP2010507577A publication Critical patent/JP2010507577A/ja
Publication of JP2010507577A5 publication Critical patent/JP2010507577A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2009533536A 2006-10-23 2007-10-18 トリアゾロピリダジンタンパク質キナーゼモジュレーター Withdrawn JP2010507577A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87138406P 2006-12-21 2006-12-21
US91375207P 2007-04-24 2007-04-24
US95283307P 2007-07-30 2007-07-30
PCT/US2007/081832 WO2008051805A2 (en) 2006-10-23 2007-10-18 Triazolo-pyridazine protein kinase modulators

Publications (2)

Publication Number Publication Date
JP2010507577A true JP2010507577A (ja) 2010-03-11
JP2010507577A5 JP2010507577A5 (OSRAM) 2010-12-02

Family

ID=39031065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533536A Withdrawn JP2010507577A (ja) 2006-10-23 2007-10-18 トリアゾロピリダジンタンパク質キナーゼモジュレーター

Country Status (16)

Country Link
US (1) US8071581B2 (OSRAM)
EP (1) EP2081937B1 (OSRAM)
JP (1) JP2010507577A (OSRAM)
KR (1) KR101083177B1 (OSRAM)
AU (1) AU2007309237B2 (OSRAM)
BR (1) BRPI0717317A2 (OSRAM)
CA (1) CA2667453A1 (OSRAM)
DK (1) DK2081937T3 (OSRAM)
EA (1) EA016527B1 (OSRAM)
ES (1) ES2393132T3 (OSRAM)
MX (1) MX2009004060A (OSRAM)
PE (1) PE20081256A1 (OSRAM)
PL (1) PL2081937T3 (OSRAM)
PT (1) PT2081937E (OSRAM)
TW (1) TW200833692A (OSRAM)
WO (1) WO2008051805A2 (OSRAM)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524385A (ja) * 2008-06-18 2011-09-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｅｔキナーゼ阻害剤としての３−（３−ピリミジン−２−イルベンジル）−１，２，４−トリアゾロ［４，３−ｂ］ピリダジン誘導体
JP2012512200A (ja) * 2008-12-18 2012-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ３−（３−ピリミジン−２−イルベンジル）−１，２，４−トリアゾロ［４，３−ｂ］ピリミジン誘導体
JP2013525371A (ja) * 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
JP2013527238A (ja) * 2010-06-01 2013-06-27 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
JP2015526486A (ja) * 2012-09-03 2015-09-10 クラウン バイオサイエンス インコーポレイテッド（台湾） 抗がん剤としての高選択性ｃ−Ｍｅｔ阻害剤
JP2016512209A (ja) * 2013-03-13 2016-04-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピン化合物の作製方法
JP2017503770A (ja) * 2013-12-09 2017-02-02 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしてのトリアゾロピリダジン誘導体

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PT2674428T (pt) 2006-04-07 2016-07-14 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
BRPI0719333A2 (pt) 2006-11-22 2014-02-04 Incyte Corp Midazotriazinas e imidazopirimidinas como inbidores de cinase
WO2009106577A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
BRPI0912882A2 (pt) 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
WO2010068292A1 (en) 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
KR20110113755A (ko) * 2009-02-10 2011-10-18 아스트라제네카 아베 트리아졸로 〔4,3-ｂ〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
JP2012519731A (ja) * 2009-03-09 2012-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ニコチン受容体およびｇａｂａａ受容体のアロステリックモジュレーターとしての置換複素環およびそれらの使用
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
IN2012DN01453A (OSRAM) 2009-08-20 2015-06-05 Novartis Ag
PL2719699T3 (pl) * 2009-12-31 2016-01-29 Hutchison Medipharma Ltd Pewne triazolopirazyny, ich kompozycje i sposoby ich stosowania
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
JP2013526570A (ja) 2010-05-14 2013-06-24 オーエスアイ・ファーマシューティカルズ，エルエルシー 縮合二環式キナーゼ阻害剤
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US20140088114A1 (en) 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
MX356683B (es) 2011-09-27 2018-06-08 Genfit Derivados de triazolpiridazinas 6-sustituidas como agonistas rev-erb.
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
KR20140144726A (ko) 2012-03-30 2014-12-19 리젠 파마슈티컬스 소시에떼 아노님 C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
ME02794B (me) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
JP6250686B2 (ja) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのヘテロアリール結合させたキノリニルモジュレータ
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
WO2014133526A1 (en) 2013-02-28 2014-09-04 Empire Technology Development Llc Colored pigment particles for electrophoretic displays
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
DK2970265T3 (en) * 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
ES2770727T3 (es) 2013-10-15 2020-07-02 Janssen Pharmaceutica Nv Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
WO2015134854A2 (en) * 2014-03-06 2015-09-11 Oyagen, Inc. Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
CA2944140C (en) 2014-04-15 2022-10-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
WO2016109492A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
RU2748884C2 (ru) 2015-07-20 2021-06-01 Джензим Корпорейшн Ингибиторы рецептора колониестимулирующего фактора-1 (csf-1r)
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN113861198B (zh) * 2020-06-30 2024-08-02 上海医药集团股份有限公司 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
AU2002251266A1 (en) 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
US7337831B2 (en) * 2001-08-10 2008-03-04 Yokohama Tlo Company Ltd. Heat transfer device
ME02736B (me) * 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524385A (ja) * 2008-06-18 2011-09-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｅｔキナーゼ阻害剤としての３−（３−ピリミジン−２−イルベンジル）−１，２，４−トリアゾロ［４，３−ｂ］ピリダジン誘導体
JP2012512200A (ja) * 2008-12-18 2012-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ３−（３−ピリミジン−２−イルベンジル）−１，２，４−トリアゾロ［４，３−ｂ］ピリミジン誘導体
JP2013525371A (ja) * 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
JP2013527238A (ja) * 2010-06-01 2013-06-27 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
JP2015526486A (ja) * 2012-09-03 2015-09-10 クラウン バイオサイエンス インコーポレイテッド（台湾） 抗がん剤としての高選択性ｃ−Ｍｅｔ阻害剤
JP2016512209A (ja) * 2013-03-13 2016-04-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピン化合物の作製方法
JP2018008959A (ja) * 2013-03-13 2018-01-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピン化合物の作製方法
KR101871133B1 (ko) 2013-03-13 2018-06-25 에프. 호프만-라 로슈 아게 벤즈옥사제핀 화합물의 제조 방법
JP2017503770A (ja) * 2013-12-09 2017-02-02 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしてのトリアゾロピリダジン誘導体

Also Published As

Publication number Publication date
KR101083177B1 (ko) 2011-11-11
EA016527B1 (ru) 2012-05-30
EP2081937A2 (en) 2009-07-29
AU2007309237A1 (en) 2008-05-02
TW200833692A (en) 2008-08-16
WO2008051805A3 (en) 2008-07-10
US8071581B2 (en) 2011-12-06
KR20090069303A (ko) 2009-06-30
ES2393132T3 (es) 2012-12-18
BRPI0717317A2 (pt) 2013-10-22
WO2008051805A2 (en) 2008-05-02
DK2081937T3 (da) 2012-10-01
EP2081937B1 (en) 2012-09-12
US20100120739A1 (en) 2010-05-13
EA200970402A1 (ru) 2009-10-30
CA2667453A1 (en) 2008-05-02
MX2009004060A (es) 2009-06-19
AU2007309237B2 (en) 2012-03-22
PE20081256A1 (es) 2008-10-13
PL2081937T3 (pl) 2013-01-31
PT2081937E (pt) 2012-10-15

Similar Documents

Publication Publication Date Title
KR101083177B1 (ko) 트리아졸로-피리다진 단백질 키나제 조정제
JP5378222B2 (ja) タンパク質キナーゼ調節物質としての二環式トリアゾール
JP6785819B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
US20240366608A1 (en) Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
AU2015271837B2 (en) Tank-binding kinase inhibitor compounds
TWI494314B (zh) ５,７－取代的－咪唑并［１,２－ｃ］嘧啶
CN101558070A (zh) 三唑并哒嗪蛋白激酶调节剂
US20220098203A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
US20220251081A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
JP5992096B2 (ja) Ｐｄｅ１０阻害剤としてのトリアゾロ化合物
CN104363908B (zh) 吡咯烷基杂环类
AU2023380028A1 (en) Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101015

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121120